HYOGO, Japan, July 21, 2026
JCR Pharmaceuticals announced that the United Arab Emirates (UAE) has granted marketing authorization for IZCARGO™ (pabinafusp alfa/JR-141), the company’s innovative blood-brain barrier (BBB)-penetrating enzyme replacement therapy (ERT) for Hunter syndrome (Mucopolysaccharidosis Type II, MPS II). The approval represents the first marketing authorization for IZCARGO outside Japan, marking a major milestone in JCR’s international expansion strategy for rare disease therapies. Approved in Japan since 2021, IZCARGO is built on JCR’s proprietary J-Brain Cargo® technology, which enables therapeutic enzymes to cross the blood-brain barrier and target both systemic and neurological manifestations of Hunter syndrome. The company is simultaneously advancing a global Phase 3 clinical trial while expanding commercialization through regional partnerships.
UAE Approval Expands Access to Innovative Rare Disease Therapy
The UAE authorization was achieved through JCR’s strategic collaboration with Taiba Middle East FZ LLC, which holds responsibility for the marketing and distribution of IZCARGO across the UAE and additional countries throughout the Middle East and North Africa (MENA) region. Regulatory approval was supported by the product’s existing authorization in Japan, allowing JCR to accelerate access for patients affected by this rare inherited disorder. Company executives described the approval as a significant international milestone that strengthens JCR’s commitment to making innovative therapies available beyond Japan. The partnership with Taiba also establishes a framework for pursuing additional regulatory approvals throughout the MENA region while expanding access to patients living with rare genetic diseases.
J-Brain Cargo Technology Targets Neurological Disease Burden
Unlike conventional enzyme replacement therapies, IZCARGO incorporates JCR’s proprietary J-Brain Cargo® platform, enabling the therapeutic enzyme to cross the blood-brain barrier through transferrin receptor-mediated transport. This differentiated mechanism allows treatment of both the systemic symptoms and central nervous system (CNS) complications associated with Hunter syndrome, an area of significant unmet medical need. Preclinical studies demonstrated successful enzyme delivery into brain tissue, reduced substrate accumulation within the CNS, and therapeutic activity across multiple organs. Clinical trials further showed reductions in cerebrospinal fluid heparan sulfate, an important biomarker associated with neurological disease progression, alongside evidence supporting improvements in CNS manifestations. These findings position IZCARGO as one of the few therapies specifically designed to address neurological complications in patients with Hunter syndrome.
Advertisement
Global Development Continues with Ongoing Phase 3 Trial
JCR continues to advance IZCARGO through an ongoing global Phase 3 clinical trial while pursuing broader international regulatory approvals. Hunter syndrome affects approximately 2,000 to 3,000 individuals worldwide and is caused by deficiency of the iduronate-2-sulfatase enzyme, leading to progressive accumulation of glycosaminoglycans throughout the body and brain. Existing enzyme replacement therapies primarily address systemic disease but have limited ability to penetrate the blood-brain barrier. By combining innovative drug delivery technology with enzyme replacement therapy, JCR aims to address one of the most significant treatment gaps in lysosomal storage disorders. Although the company indicated the UAE approval is not expected to materially impact fiscal year 2026 financial results, the authorization establishes an important foundation for continued international commercialization and expansion of its rare disease portfolio.
Source: JCR Pharmaceuticals press release
